Maxim Group set a $14.00 target price on Mesoblast limited (NASDAQ:MESO) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the stock.

“Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet.”,” the firm’s analyst commented.

Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald reiterated a buy rating on shares of Mesoblast limited in a research note on Wednesday. BidaskClub lowered shares of Mesoblast limited from a sell rating to a strong sell rating in a research note on Friday, July 28th. Credit Suisse Group set a $11.00 price target on shares of Mesoblast limited and gave the company a hold rating in a research note on Tuesday, July 18th. Finally, Zacks Investment Research upgraded shares of Mesoblast limited from a sell rating to a hold rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $12.70.

Mesoblast limited (NASDAQ MESO) opened at 6.24 on Wednesday. The company has a 50-day moving average price of $7.20 and a 200-day moving average price of $8.23. The firm’s market cap is $529.68 million. Mesoblast limited has a one year low of $4.01 and a one year high of $12.50.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

A hedge fund recently raised its stake in Mesoblast limited stock. Princeton Capital Management Inc. boosted its stake in Mesoblast limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned about 0.20% of Mesoblast limited worth $1,398,000 at the end of the most recent quarter. 2.95% of the stock is currently owned by hedge funds and other institutional investors.

About Mesoblast limited

Receive News & Stock Ratings for Mesoblast limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast limited and related stocks with our FREE daily email newsletter.